4.7 Article

Lymph node stromal cells acquire peptide-MHCII complexes from dendritic cells and induce antigen-specific CD4+ T cell tolerance

Journal

JOURNAL OF EXPERIMENTAL MEDICINE
Volume 211, Issue 6, Pages 1153-1166

Publisher

ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20132000

Keywords

-

Funding

  1. Clinical Research Priority Program (CRPP) Multiple Sclerosis of the University of Zurich, Zurich, Switzerland
  2. Swiss National Science Foundation [310030-127042, 31-135756]
  3. European Research Council [281365, 323053]
  4. Leenaards Foundation
  5. Swiss National Science Foundation (SNF) [310030_127042] Funding Source: Swiss National Science Foundation (SNF)
  6. European Research Council (ERC) [323053, 281365] Funding Source: European Research Council (ERC)

Ask authors/readers for more resources

Dendritic cells (DCs), and more recently lymph node stromal cells (LNSCs), have been described to tolerize self-reactive CD8(+) T cells in LNs. Although LNSCs express MHCII, it is unknown whether they can also impact CD4(+) T cell functions. We show that the promoter IV (pIV) of class II transactivator (CIITA), the master regulator of MHCII expression, controls endogenous MHCII expression by LNSCs. Unexpectedly, LNSCs also acquire peptide- MHCII complexes from DCs and induce CD4(+) T cell dysfunction by presenting transferred complexes to naive CD4(+) T cells and preventing their proliferation and survival. Our data reveals a novel, alternative mechanism where LN-resident stromal cells tolerize CD4(+) T cells through the presentation of self-antigens via transferred peptide-MHCII complexes of DC origin.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available